Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, Phase 1b study in participants with locally advanced rectum cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by magnetic resonance imaging (MRI). It is conducted to assess the safety, to assess the tolerability, and to determine the recommended Phase 2 dose (RP2D) of E7046 in combination with pre-operative chemoradiotherapy. The study will also assess the efficacy of the combination in the expansion part at RP2D.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03152370
Study type Interventional
Source Adlai Nortye Biopharma Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date May 17, 2017
Completion date September 30, 2021